June 10, 2019

NCCN Guidelines Panel: Breast Cancer

On behalf of Puma Biotechnology, Inc., I respectfully request the NCCN Breast Cancer Guideline Panel consider referencing the NCCN Guidelines for Central Nervous System Cancers.

Although the incidence of breast cancer with brain metastases (BCMB) is ~10-15% of unselected patients with advanced disease, up to half will eventually develop BCBM and recurrent CNS events remain a major source of patient morbidity and mortality.1-4

Specific Changes: Please consider referencing the NCCN CNS guideline for breast cancer disease on pages BINV-18 and MS-66.

Sincerely,

[Signature]

Deepa Lalla, B.Pharm, PhD
Head of Medical Affairs
Puma Biotechnology, Inc.

References


